NCT01509469

Brief Summary

The purpose of this study is to determine whether ileal infusion of casein and sucrose can activate the ileal brake.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable obesity

Timeline
Completed

Started Mar 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2011

Completed
5 months until next milestone

First Posted

Study publicly available on registry

January 13, 2012

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

January 29, 2014

Status Verified

January 1, 2014

Enrollment Period

1.3 years

First QC Date

August 9, 2011

Last Update Submit

January 28, 2014

Conditions

Keywords

Ileal brakeCaseinSucroseIleal infusion

Outcome Measures

Primary Outcomes (1)

  • Difference in satiation (as measured by VAS) and food intake as measured during an ad libitum meal

    1 day

Secondary Outcomes (6)

  • Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Cholecystokinin (CCK)

    1 day

  • Gastric emptying by using the C13 stable isotope breath test

    1 day

  • Small bowel transit time by using lactulose hydrogen breath test

    1 day

  • Gallbladder volumes by gallbladder ultrasound

    1 day

  • Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Glucagon Like Peptide-1 (GLP-1)

    1 day

  • +1 more secondary outcomes

Study Arms (6)

Low dose casein

EXPERIMENTAL

Ileal infusion of low dose casein

Dietary Supplement: Casein

High dose casein

EXPERIMENTAL

Ileal infusion of high dose casein

Dietary Supplement: Casein

Low dose sucrose

EXPERIMENTAL

Ileal infusion of low dose sucrose

Dietary Supplement: Sucrose

High dose sucrose

EXPERIMENTAL

Ileal infusion of high dose sucrose

Dietary Supplement: Sucrose

Placebo

PLACEBO COMPARATOR

Ileal infusion saline

Other: Saline

Safflower oil

ACTIVE COMPARATOR

Ileal infusion safflower oil

Dietary Supplement: Safflower oil

Interventions

CaseinDIETARY_SUPPLEMENT

Ileal infusion of low dose casein (5 gram)

Low dose casein
SucroseDIETARY_SUPPLEMENT

Ileal infusion of low dose sucrose (4.3 gram)

Low dose sucrose
SalineOTHER

Ileal infusion with saline (180mL in total)

Placebo
Safflower oilDIETARY_SUPPLEMENT

Ileal infusion with safflower oil (6gr safflower oil in water)

Safflower oil

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Based on medical history and previous examination, no gastrointestinal complaints can be defined.
  • Age between 18 and 55 years. This study will include healthy adult subjects (Male and Female), Women must be taking oral contraceptives. Subjects over 55 years have an increased risk for comorbidities, therefore, subjects over 55 years will not be included.
  • BMI between 18 and 29 kg/m2
  • Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)
  • Weight stable over at least the last 6 months

You may not qualify if:

  • History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
  • Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing
  • Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
  • Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
  • Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic)
  • Pregnancy, lactation
  • Excessive alcohol consumption (\>20 alcoholic consumptions per week)
  • Smoking
  • Blood donation within 3 months before the study period
  • Self-admitted HIV-positive state
  • Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)
  • Lactose or cow milk intolerance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University Medical Center

Maastricht, Limburg, Netherlands

Location

Related Publications (1)

  • Ripken D, van Avesaat M, Troost FJ, Masclee AA, Witkamp RF, Hendriks HF. Intraileal casein infusion increases plasma concentrations of amino acids in humans: A randomized cross over trial. Clin Nutr. 2017 Feb;36(1):143-149. doi: 10.1016/j.clnu.2016.01.012. Epub 2016 Jan 29.

MeSH Terms

Conditions

ObesityOverweight

Interventions

CaseinsSucroseSodium ChlorideSafflower Oil

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Milk ProteinsAnimal Proteins, DietaryDietary ProteinsProteinsAmino Acids, Peptides, and ProteinsPhosphoproteinsDisaccharidesOligosaccharidesPolysaccharidesCarbohydratesSugarsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsDietary Fats, UnsaturatedDietary FatsFatsLipidsFats, UnsaturatedPlant OilsOilsPlant PreparationsBiological ProductsComplex MixturesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • A. Masclee, Prof.

    Maastricht University Medical Centre +

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

August 9, 2011

First Posted

January 13, 2012

Study Start

March 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

January 29, 2014

Record last verified: 2014-01

Locations